The two simultaneous Incyte trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.

Topline data were announced from pivotal phase 3 studies evaluating povorcitinib in adults with moderate to severe hidradenitis suppurativa.

Incyte (INCY) announced topline results from its Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib, an ...

Biopharmaceutical company Incyte (Nasdaq: INCY) has reported encouraging results from its Phase 3 STOP-HS clinical trials ...

Also Read: Eli Lilly-Incyte Partnered FDA-Approved Drug Shows Encouraging Efficacy In Adolescent Patients With Patchy Hair ...

In the Phase III STOP-HS1 and STOP-HS2 trials, results show that patients treated with povorcitinib for hidradenitis suppurativa experienced a ≥50% reduction in the total abscess and inflammatory ...

Incyte (NASDAQ:INCY) recently announced that it had achieved positive results from both of its phase 3 studies STOP-HS1 and STOP-HS2. Both of these late-stage studies were using the company's drug ...

Both the STOP-HS1 and STOP-HS2 studies met their primary endpoint at both tested doses (45 mg and 75 mg). A significantly higher proportion of patients treated with povorcitinib once daily (QD) versus ...

Newly released data from the phase 3 STOP-HS clinical trial program reveal positive results in hidradenitis suppurativa from ...

US biotech Incyte (Nasdaq: INCY) has reported positive results from two Phase III trials of povorcitinib, an oral JAK1 ...

Incyte declines as data from phase III studies on povorcitinib, for the treatment of hidradenitis suppurativa, fail to meet investor expectations.